MAOA and Alzheimer disease: Over the past decade, important efforts have gone into developing multitarget compounds for AD, many of them focused on combining pharmacophores already used for the disease, such as the combination of rivastigmine and rasagline to yield ladostigil [(3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-inden-5-yl] N-ethyl-N-methylcarbamate, which was created as an AChE and monoamine oxidase (MAO-A and -B) inhibitor also having an effect on oxidative stress and reaching clinical trial phase II [17,18].